Larvol Delta - Atossa-Therapeutics-Receives-Second-Positive-Interim-Safety-Assessment-in-Clinical-Study-of-AT301-Nasal-Spray-Being-Developed-for-the-Coronavirus-Causing-COVID

AT-301 - Atossa Therap

https://www.globenewswire.com/news-release/2020/09/17/2095284/0/en/Atossa-Therapeutics-Receives-Second-Positive-Interim-Safety-Assessment-in-Clinical-Study-of-AT-301-Nasal-Spray-Being-Developed-for-the-Coronavirus-Causing-COVID.html

Sep 17, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next